Abstracts tagged "Wegener’s granulomatosis and polyangiitis"

Abstract Number: 1664 • ACR/ARP Annual Meeting 2019
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Pierre Charles¹, Agnes Dechartres ², Benjamin Terrier ³, Pascal Cohen ³, Stanislas Faguer ⁴, Antoine Huart ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Bernard Bonnotte ⁶, Maxime Samson ⁷, Alexandre Karras ⁸, Noémie Jourde-Chiche ⁹, François Lifermann ¹⁰, Pierre Gobert ¹¹, Catherine Hanrotel-Saliou ¹², Pascal Godmer ¹³, Nicolas Martin-Silva ¹⁴, Grégory Pugnet ¹⁵, Marie Matignon ¹⁶, Olivier Aumaitre ¹⁷, Jean-François Viallard ¹⁸, François Maurier ¹⁹, Nadine Meaux Ruault ²⁰, Sophie Rivière ²¹, Jean Sibilia ²², Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³ and Loic Guillevin ³, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nantes, Nantes, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷CHU Dijon, Dijon, France, ⁸Paris HEGP, Paris, France, ⁹APHM, Marseille, Marseille, France, ¹⁰CH Dax, Dax, France, ¹¹CH Avignon, Avignon, France, ¹²CHU Brest, Brest, France, ¹³CH Bretagne-Atlantique, Vannes, France, ¹⁴CHU Caen, Caen, France, ¹⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁶APHP, Créteil, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Bordeaux, Bordeaux, France, ¹⁹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ²⁰CHU Besançon, Besançon, France, ²¹CHU Montpellier, Montpellier, France, ²²CHU Strasbourg, Strasbourg, France
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…